TITLE

A randomized controlled pilot study to compare capecitabine-oxaliplatin with 5-FU-leucovorin as neoadjuvant concurrent chemoradiation in locally advanced adenocarcinoma of rectum

AUTHOR(S)
Saha, Animesh; Ghosh, Sajal Kumar; Roy, Chhaya; Saha, Makhan Lal; Choudhury, Krishnangshu Bhanja; Chatterjee, Koushik
PUB. DATE
January 2015
SOURCE
Journal of Cancer Research & Therapeutics;Jan-Mar2015, Vol. 11 Issue 1, p88
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Context: Established as an adjuvant chemotherapy, CapeOX has recently been shown to have radiosensitizer property in a phase I and II studies, with appreciable downstaging and tolerable toxicities. Aims: The study was designed to evaluate whether the capecitabine-oxaliplatin combination was superior to 5-fluorouracil (5-FU)-leucovorin as radiosensitizer for neoadjuvant chemoradiation in downstaging locally advanced rectal adenocarcinoma and to compare the toxicities between the two arms. Settings and Design: Single institutional, double blinded, prospective, noncrossover, randomized control pilot study. Subjects and Methods: In arm A (n = 21), patients received capecitabine (1,000 mg/m² daily) in twice dailydoseon days 1-14 and 25-38 and oxaliplatin (85mg/m²) intravenous (IV) over 2 h, on D1 and D29. In arm B (n = 21), patients received leucovorin (20mg/m²) and 5-FU (350mg/m²) from D1-5 and D29-33. Patient in both the arms received concurrent radiation (50.4 Gy in 28 #, in conventional fractionation of 1.8 Gy per fraction). Six to eight weeks after concurrent chemoradiation, patients underwent assessment and surgery with total mesorectal resection. Postoperatively, adjuvant chemotherapy with m-FOLFOX 6 of 4 months was given to all patients. Statistical Analysis Used: Chi-square test was used to compare categorical variables between the groups. Results: Objective response rate (ORR) in arm A was 80.95% compared to arm B which had 66.66% (P = 0.3055). Pathological complete response (pCR) rate of arm A was comparable to arm B (23.8vs 14.28%, P value = 0.6944). Surgery with R0 resection was possible in 80.95% cases of arm A compared to 66.66% cases of arm B (P = 0.4827). Grade III toxicities were quite comparable between two treatment arms. Conclusions: In terms of ORR, pCR rate, R0 resection, and toxicity profile; both the arms were comparable.
ACCESSION #
102360877

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics